Journal of Neural Transmission

, Volume 38, Issue 3–4, pp 181–191 | Cite as

In vivo assessment of decarboxylase inhibition or potentiation: Urinary dopamine and L-Dopa output after L-Dopa administration

  • R. D. Johnson
  • C. R. J. Ruthven
  • B. L. Goodwin
  • M. Sandler
Article
Received:

Summary

In the L-Dopa treated rat, a decreased urinary output of free and conjugated dopamine and an increase in free and conjugated L-Dopa excretion after administration of decarboxylase-inhibiting drugs provide a goodin vivo index of Dopa decarboxylase inhibition. With the exception of free dopamine output, which showed an equivocal change, these measurements appear to provide a good yardstick of decarboxylase status in man also. Using this approach, it was not possible to find any evidence of facilitation of decarboxylase action, in L-Dopa-treated parkinsonians given pyridoxine supplements, to account for the ability of this compound to neutralize the beneficial effect of L-Dopa.

Keywords

Public Health Dopamine Beneficial Effect Pyridoxine Urinary Output 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andén, N.-E., Carlsson, A., Kerstell, J., Magnusson, T., Olsson, R., Roos, B.-E., Steen, B., Steg, G., Svanhorg, A., Thieme, G., Werdinius, B.: Oral L-dopa treatment of parkinsonism. Acta med. Scand.187 247 to 255 (1970).Google Scholar
  2. Bartholini, G., Burkard, W. P., Pletscher, A., Bates, H. M.: Increase of cerebral catecholamines caused by 3, 4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature215, 852–853 (1967).Google Scholar
  3. Borud, O., Midtvedt, T., Gjessing, L. R.: Urinary metabolites from rats given L-Dopa. Acta Pharmacol. Toxicol.31, 540–549 (1972).Google Scholar
  4. Burkard, W. P., Gey, K. F., Pletscber, A.: A new inhibitor of decarboxylase of aromatic amino acids. Experientia18, 411–412 (1962).Google Scholar
  5. Calne, D. B., Sandler, M.: L-Dopa and parkinsonism. Nature226, 21–24 (1970).Google Scholar
  6. Constantinidis, J., de la Torre, J. C., Tissot, R., Geissbuhler, F.: La barrière capillaire pour la dopa dans le cerveau et les différents organes. Psychopharmacologia15, 75–87 (1969).Google Scholar
  7. Cotzias, G. C.: Metabolic modification of some neurologie disorders. J. Amer. med. Ass.210, 1255–1262 (1969).Google Scholar
  8. Cotzias, G. G., Papavasiliou, P. S., Gellene, R.: Modification of parkinsonism — chronic treatment with L-Dopa. New Engl. J. Med.280, 337–345 (1969).Google Scholar
  9. Dunner, D. L., Brodie, H. H., Goodwin, F. K.: Plasma Dopa response to levodopa administration in man: Effects of a peripheral decarboxylase inhibitor. Clin. Pharmacol. Therap.12, 212–217 (1971).Google Scholar
  10. Duvoisin, R. C., Yahr, M. D., Cote, L. D.: Pyridoxine reversal of L-Dopa effects in Parkinsonism. Trans. Amer. neurol. Ass.94, 81–82 (1969).Google Scholar
  11. Goodwin, B. L., Karoum, F., Ruthven, C. R. J., Sandler, M.: Sources of contamination during a GLC-electron capture detection assay of phenolic alcohols. Clin. chim. Acta40, 269–272 (1972).Google Scholar
  12. Holtz, P.: Role of L-Dopa decarboxylase in the biosynthesis of catecholamines in nervous tissue and the adrenal medulla. Pharmacol. Rev.11, 317–329 (1959).Google Scholar
  13. Holtz, P., Credner, K., Koepp, W.: Die enzymatische Entstehung von Oxytyramin im Organismus und die physiologische Bedeutung der Dopa-decarboxylase. Arch. exp. Pathol. Pharmakol.200, 356–388 (1942).Google Scholar
  14. Holtz, P., Heise, R., Lüdke, K.: Fermentativer Abbau von L-Dioxyphenylalanin (dopa) durch Niere. Arch. exp. Pathol. Pharmakol.191, 87–118 (1938).Google Scholar
  15. Holtz, P., Palm, D.: Pharmacological aspects of vitamin B6. Pharmacol. Rev.16, 113–178 (1964).Google Scholar
  16. Hornykiewicz, O.: Dopamine in the basal ganglia: its role and therapeutic implications (including the clinical use of L-Dopa). Br. Med. Bull.29, 172–178 (1973).Google Scholar
  17. Johnstone, G. A. R.: L-Dopa and vitamin B6. LancetII, 220–221 (1971).Google Scholar
  18. Lloyd, K., Hornykiewicz, O.: Occurrence and distribution of L-Dopa decarboxylase in the human brain. Brain Res.22, 426–428 (1970 a).Google Scholar
  19. Lloyd, K., Hornykiewicz, O.: Parkinson's disease: activity of L-Dopa decarboxylase in discrete brain regions. Science170, 1212–1213 (1970 b).Google Scholar
  20. Lovenberg, W., Weissbach, H., Udenfriend, S.: Aromatic L-amino acid decarboxylase. J. biol. Chem.237, 89–93 (1962).Google Scholar
  21. Messiha, F. S., Hsu, T. H., Bianchine, J. R.: Effects of a peripheral aromatic L-amino acids decarboxylase inhibitor on L-[2-14C]-3, 4-dihydroxy-phenylalanine metabolism in man. Biochem. Pharmacol.21, 2144–2147 (1972).Google Scholar
  22. Morgan, C. D., Ruthven, C. R. J., Sandler, M.: The quantitative assessment of isoprenaline metabolism in man. Clin. chim. Acta16, 381–386 (1969).Google Scholar
  23. O'Gorman, L. P., Borud, O., Khan, I. A., Gjessing, L. R.: The metabolism of L-3, 4-dihydroxyphenylalanine in man. Clin. chim. Acta29, 111 to 119 (1970).Google Scholar
  24. Pare, C. M. B., Sandler, M., Stacey, R. S.: Decreased 5-hydroxytryptophan decarboxylase activity in phenylketonuria. LancetII, 1099–1101 (1958).Google Scholar
  25. Porter, C. C., Watson, L. S., Titus, D. C., Totaro, J. A., Byer, S. S.: Inhibition of Dopa decarboxylase by the hydrazino analog of α-methyldopa. Biochem. Pharmacol.11, 1067–1077 (1962).Google Scholar
  26. Rutledge, C. O., Hoehn, M. H.: Sulphate conjugation and L-Dopa treatment of Parkinsonian patients. Nature244, 447–450 (1973).Google Scholar
  27. Sandler, M.: Catecholamine synthesis and metabolism in man (with special reference to parkinsonism). In: Handbook of Experimental Pharmacology, Vol. 33, Catecholamines (Blaschko, H., Muscholl, E., eds.), pp. 845–899. Berlin-Heidelberg-New York: Springer. 1972.Google Scholar
  28. Sandier, M., Ruthven, C. R. J.: The biosynthesis and metabolism of the catecholamines. In: Progress in Medical Chemistry (Ellis, G. P., West, G. B., eds.), Vol. 6, pp. 200–265. London: Butterworth. 1969.Google Scholar
  29. Sandler, M., Ruthven, C. R. J., Ceasar, P. M.: Urinary pH and the excretion of biologically active monoamines and their acidic metabolites. Proc. 7th Int. Congr. Biochem., Tokyo, 971 (1967).Google Scholar
  30. Wong, K. P., Ruthven, C. R. J., Sandler, M.: Gas Chromatographie measurement or urinary catecholamines by an electron capture procedure. Clin. chim. Acta47, 215–222 (1973).Google Scholar
  31. Wong, K. P., Sandler, M.: A gas Chromatographie method for measuring dopa decarboxylase activity in tissues. Clin. chim. Acta50, 119–128 (1974).Google Scholar

Copyright information

© Springer-Verlag 1976

Authors and Affiliations

  • R. D. Johnson
    • 1
  • C. R. J. Ruthven
    • 1
  • B. L. Goodwin
    • 1
  • M. Sandler
    • 1
  1. 1.Bernhard Baron Memorial Research Laboratories and Institute of Obstetrics and GynaecologyQueen Charlotte's Maternity HospitalLondonUK

Personalised recommendations